EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Pages:

16

TR-1 notification of major interest in shares

12^th Jul 2016

Director / PDMR Shareholding

12^th Jul 2016

Directorate Change

11^th Jul 2016

EKF Diagnostics announces the appointment of Carl Dominic Contadini, an Operational Adviser to Harwood Capital LLP, as Non-Executive Director with immediate effect.

6^th Jul 2016

EKF Diagnostics Holdings plc provides the following update on trading for the six months ended 30 June 2016.

Director / PDMR Shareholding

27^th Jun 2016

Director / PDMR Shareholding

24^th Jun 2016

Director / PDMR Shareholding

22^nd Jun 2016

TR-1 notification of major interest in shares

22^nd Jun 2016

Director/PDMR Shareholding

21^st Jun 2016

Director Dealings

10^th Jun 2016

Pages:

16

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Purchase of own shares and PDMR Dealing

EKF Diagnostics announces an update in relation to its previously announced Buy-Back.

Total voting rights

The Company's total issued share capital consists of 455,163,766 ordinary shares of 1 pence each with one voting right per share.

Purchase of own shares and PDMR Dealing

EKF Diagnostics announces an update to its prior announcement on 14 November 2018 in relation to the Buy-Back.

Purchase of own shares and PDMR Dealing

The Company confirms that on 20 November 2018, it purchased 1,641,493 of its ordinary shares on the London Stock Exchange at a price of 27.4348 pence per share. The purchased shares will be cancelled.

Purchase of own shares and PDMR Dealing

The Company confirms that on 19 November 2018, it purchased 178,423 of its ordinary shares on the London Stock Exchange at a price of 26.15 pence per share. The purchased shares will be cancelled.

Product showcase

Copyright © 2022 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

ekf orange

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | UK Modern Slavery Act